首页> 美国卫生研究院文献>Assay and Drug Development Technologies >Development of a QPatch Automated Electrophysiology Assay for Identifying KCa3.1 Inhibitors and Activators
【2h】

Development of a QPatch Automated Electrophysiology Assay for Identifying KCa3.1 Inhibitors and Activators

机译:用于识别KCa3.1抑制剂和激活剂的QPatch自动电生理测定方法的开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The intermediate-conductance Ca2+-activated K+ channel KCa3.1 (also known as KCNN4, IK1, or the Gárdos channel) plays an important role in the activation of T and B cells, mast cells, macrophages, and microglia by regulating membrane potential, cellular volume, and calcium signaling. KCa3.1 is further involved in the proliferation of dedifferentiated vascular smooth muscle cells and fibroblast and endothelium-derived hyperpolarization responses in the vascular endothelium. Accordingly, KCa3.1 inhibitors are therapeutically interesting as immunosuppressants and for the treatment of a wide range of fibroproliferative disorders, whereas KCa3.1 activators constitute a potential new class of endothelial function preserving antihypertensives. Here, we report the development of QPatch assays for both KCa3.1 inhibitors and activators. During assay optimization, the Ca2+ sensitivity of KCa3.1 was studied using varying intracellular Ca2+ concentrations. A free Ca2+ concentration of 1 μM was chosen to optimally test inhibitors. To identify activators, which generally act as positive gating modulators, a lower Ca2+ concentration (∼200 nM) was used. The QPatch results were benchmarked against manual patch-clamp electrophysiology by determining the potency of several commonly used KCa3.1 inhibitors (TRAM-34, NS6180, ChTX) and activators (EBIO, riluzole, SKA-31). Collectively, our results demonstrate that the QPatch provides a comparable but much faster approach to study compound interactions with KCa3.1 channels in a robust and reliable assay.
机译:中间电导Ca 2 + 激活的K + 通道KCa3.1(也称为KCNN4,IK1或Gárdos通道)在激活C 2 中起重要作用。 T和B细胞,肥大细胞,巨噬细胞和小胶质细胞可通过调节膜电位,细胞体积和钙信号传导来调节。 KCa3.1进一步参与去分化的血管平滑肌细胞的增殖以及在血管内皮中的成纤维细胞和内皮衍生的超极化反应。因此,KCa3.1抑制剂作为免疫抑制剂和广泛的纤维增生性疾病的治疗在治疗上是令人感兴趣的,而KCa3.1活化剂构成了潜在的一类新的保留高血压的内皮功能。在这里,我们报告了针对KCa3.1抑制剂和激活剂的QPatch检测方法的发展。在优化分析过程中,使用不同的细胞内Ca 2 + 浓度研究了KCa3.1的Ca 2 + 敏感性。选择游离Ca 2 + 浓度为1μm以最佳地测试抑制剂。为了鉴定通常用作正门控调节剂的活化剂,使用了较低的Ca 2 + 浓度(约200 nM)。通过确定几种常用的KCa3.1抑制剂(TRAM-34,NS6180,ChTX)和激活剂(EBIO,利鲁唑,SKA-31)的效力,将QPatch结果与手动膜片钳电生理学进行了对比。总的来说,我们的结果表明,QPatch提供了一种可比较但更快的方法,可以在可靠而可靠的分析中研究化合物与KCa3.1通道的相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号